plazomicin + metformin

Plazomicin + metformin is a combination of two pharmaceuticals: **plazomicin**, a next-generation aminoglycoside antibiotic engineered for activity against multidrug-resistant Enterobacteriaceae, and **metformin**, an oral biguanide antihyperglycemic agent used primarily for glycemic control in type 2 diabetes mellitus. Plazomicin acts by binding to the bacterial 30S ribosomal subunit, inhibiting protein synthesis, and is primarily indicated for complicated urinary tract infections (cUTI). Metformin decreases hepatic glucose production, increases peripheral glucose uptake, and improves insulin sensitivity. No specific combination product of plazomicin and metformin is marketed, and coadministration does not result in a clinically meaningful pharmacokinetic interaction. The drugs are typically administered separately as part of distinct therapeutic regimens[1][3][5].